Key result
Pembrolizumab linked to ~23% lower mortality in lung adenocarcinoma, despite higher cardiovascular risks.
Why the study?
Pembrolizumab improves survival in advanced lung adenocarcinoma, but potential cardiovascular toxicity remains.
Does pembrolizumab initiation within 1 year of diagnosis reduce all-cause mortality or increase major cardiovascular events (MI, ischemic stroke, heart failure) in patients with newly diagnosed lung adenocarcinoma?
Cohort (n=39,192)
Yes
Does pembrolizumab initiation within 1 year of diagnosis reduce all-cause mortality or increase major cardiovascular events (MI, ischemic stroke, heart failure) in patients with newly diagnosed lung adenocarcinoma?
Answers are grounded in this paper and cite their sources.
In a nationwide cohort of patients with lung adenocarcinoma, pembrolizumab therapy was associated with a 23% reduction in all-cause mortality alongside significantly elevated risks of heart failure, ischemic stroke, and atrial fibrillation, highlighting the need for proactive cardio-oncologic surveillance.
BACKGROUND: Pembrolizumab improves survival in advanced lung adenocarcinoma, but potential cardiovascular toxicity remains. OBJECTIVES: This study evaluated the oncologic benefits and cardiovascular risks of pembrolizumab in a nationwide lung adenocarcinoma cohort. METHODS: We analyzed 39,192 patients newly diagnosed with lung adenocarcinoma between 2012 and 2019 using the nationwide cancer registry. We compared 573 patients treated with pembrolizumab within 1 year of diagnosis with 38,619 patients who were not treated within 3 years. The outcomes included all-cause mortality and myocardial infarction (MI), ischemic stroke (IS), heart failure (HF), pericarditis/myocarditis, and atrial fibrillation (AF) over a 3-year follow-up. RESULTS: During a median follow-up of 3.0 years (IQR: 1.0-3.0 years), 18,241 deaths, 574 MI, 1,157 IS, 2,777 HF, 852 pericarditis/myocarditis, and 1,601 AF events occurred. Model-based adjusted outcome curves showed lower all-cause mortality among users (adjusted P < 0.001) but higher incidences of IS, HF, and AF (adjusted P = 0.028, <0.001, and 0.048, respectively). Nonsignificant trends toward increased risks of MI and pericarditis/myocarditis were observed. Multivariable survival analyses, including Fine-Gray competing risk models for nonfatal cardiovascular outcomes, showed that pembrolizumab use was associated with lower all-cause mortality (HR: 0.77; 95% CI: 0.69-0.86) but with increased risks of IS (HR: 1.56, 95% CI: 1.10-2.23), HF (HR: 2.72, 95% CI: 2.24-3.30), and AF (HR: 1.47, 95% CI: 1.08-2.01); increases in MI and pericarditis/myocarditis were nonsignificant. CONCLUSIONS: Pembrolizumab was associated with lower all-cause mortality but higher risks of major cardiovascular events. These findings support vigilant cardio-oncologic monitoring in patients treated with pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) conducted a cohort in Lung adenocarcinoma (n=39,192). Pembrolizumab initiated within 1 year of lung adenocarcinoma diagnosis vs. Pembrolizumab-naïve patients (not treated within 3 years of diagnosis) was evaluated on All-cause mortality within 3 years after cancer diagnosis (HR 0.77, 95% CI 0.69-0.86, p=<0.001). Pembrolizumab use reduced all-cause mortality while increasing heart failure and ischemic stroke risks in lung adenocarcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: